DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015 September 28, 2015 • 8:21 AM EDT
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015 September 10, 2015 • 7:05 AM EDT
DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer September 8, 2015 • 11:30 AM EDT
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update September 4, 2015 • 7:30 AM EDT
DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer September 2, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 August 27, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015 August 25, 2015 • 7:35 AM EDT
DelMar Pharmaceuticals to Present VAL-083 Lung Cancer Clinical Strategy at the 16th World Conference on Lung Cancer August 24, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering August 20, 2015 • 7:35 AM EDT
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083 August 17, 2015 • 8:05 AM EDT